Genomics and oncogenesis of childhood brain tumors

This team belongs to the UMR 981 - Molecular predictors and new targets in oncology

The GOBT team is dedicated to understand the development mechanisms of pediatric brain tumors (in particular gliomas). We are looking for biological markers to identify these tumors more precisely, to understand their origin, to define their prognosis and to invent new treatments.

Que faire en cas d’effets secondaires ?

Prenez rapidement contact avec votre médecin oncologue référent du DITEP.

La semaine de 9 h à 17 h

Poste de soins infirmiers
 Tél : +33 (0)1 42 11 43 27

Le soir et le week-end exclusivement

Urgences
Tél : +33 (0)1 42 11 50 00

Portable d’astreinte du DITEP
Tél : +33 (0)7 77 70 13 02

Eligibilité à un essai clinique précoce

Pour savoir si vous êtes éligible à un essai précoce, votre cancérologue doit :

New drugs for new treatments

An early clinical trial (or phase I trial) aims to assess the safety in use of a new drug (administered on its own or combined with another therapy), what happens to it in the body, the possible adverse effects in man, and to acquire initial information about its anti-tumour activity.   

At Gustave Roussy early trials are conducted by the Department of Therapeutic Innovations and Early Trials (DITEP).

Description

The Gustave Roussy Surgical and Interventional Department is responsible for surgical treatment of cancer in adults in the following specialties: gastroenterology, dermatology, ENT, breast disease, gynaecology and endocrinology, as well as surgical treatment of sarcomas.

Organisation

The Department includes several units:

Radiotherapy machines

Gustave Roussy has comprehensive technical resources covering the majority of currently performed radiotherapy techniques. Some 4,000 treatments are carried out per year.   

Stereotactic radiotherapy